| __timestamp | Dynavax Technologies Corporation | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 1244910 |
| Thursday, January 1, 2015 | 22180000 | 5029636 |
| Friday, January 1, 2016 | 37257000 | 4846776 |
| Sunday, January 1, 2017 | 27367000 | 5329003 |
| Monday, January 1, 2018 | 64770000 | 7121000 |
| Tuesday, January 1, 2019 | 74986000 | 9128000 |
| Wednesday, January 1, 2020 | 79256000 | 10731000 |
| Friday, January 1, 2021 | 100156000 | 10701000 |
| Saturday, January 1, 2022 | 131408000 | 16121000 |
| Sunday, January 1, 2023 | 152946000 | 37021000 |
Cracking the code
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech firms: Viking Therapeutics, Inc. and Dynavax Technologies Corporation, from 2014 to 2023.
Dynavax has seen a significant upward trend in SG&A expenses, with a staggering 760% increase over the decade. Starting at approximately $17.8 million in 2014, their expenses soared to $152.9 million by 2023. This growth reflects their aggressive expansion and investment in marketing and administrative capabilities.
In contrast, Viking Therapeutics exhibited a more conservative growth in SG&A expenses, rising from $1.2 million in 2014 to $37 million in 2023, marking a 2,875% increase. This indicates a strategic scaling of operations, aligning with their growth trajectory.
Both companies showcase distinct strategies in managing operational costs, offering insights into their business models and market positioning.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Dynavax Technologies Corporation
Novartis AG and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of argenx SE and Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Viking Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Dynavax Technologies Corporation
Comparing SG&A Expenses: Amneal Pharmaceuticals, Inc. vs Viking Therapeutics, Inc. Trends and Insights
Viking Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated vs Dynavax Technologies Corporation: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.